New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novavax, Inc.

NVAX

Healthcare Biotechnology

Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.

Revenue
−3.05%
EPS
n/m
Free cash flow
n/m
Total debt
+19.3%

Quarter to September 2026, against a year earlier

7.74 0.01 +0.13%
Market cap
$1.3B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
−1.0×
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, Sep 30, 2026

It holds $328.8M more in cash and short-term investments than it owes in debt. Debt has risen from $246.3M to $293.6M since Q4 FY25. Liabilities are $216.9M more than assets: shareholders’ equity is negative. What is a balance sheet?

Sep 30, 2026 · total $888.0M

Owns

$180.0MLong-term assets
$85.6MOther short-term assets
$622.4MCash & short-term investments

Funded by

$811.2MOther liabilities
$293.6MDebt

Debt is 33.1% of the total; liabilities are $216.9M more than assets.

Net cash fell from 42% of assets to 37% since Q4 FY25.

Total assetsNet debt (debt less cash)Net debt ÷ assets (right axis)
Assets and net debt, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Total assets$1.2B$1.0B$956M$888M
Net debt (debt less cash)−$500M−$497M−$426M−$329M
Net debt ÷ assets (right axis)−42.5%−47.7%−44.6%−37.0%
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Total current assets
707.96 771.10 850.82 978.28
Total non-current assets
180.05 184.48 192.35 198.24
Total Assets
888.01 955.58 1,043.16 1,176.51
Total current liabilities
329.85 330.57 342.46 459.95
Total non-current liabilities
775.02 815.71 845.46 844.32
Total liabilities
1,104.86 1,146.28 1,187.92 1,304.27
Common Equity (Total)
(216.85) (190.71) (144.76) (127.75)
Shareholders Equity (Total)
(216.85) (190.71) (144.76) (127.75)
Total Debt
293.61 293.21 292.95 246.30

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026